Sign in
IMGN Stock Price, Chart, Stats & News
ImmunoGen, Inc.
Save
8.73B
Market cap
–
Current P/E
–
Forward P/E
IMGN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.84% |
Operating margin | -203.06% |
Pretax margin | -203.81% |
Net margin | -204.93% |
Effective tax rate | -0.55% |
ROA | -63.89% |
ROE | -92.61% |
D/E | 0.10x |
Interest coverage ratio | -53.04x |
IMGN valuation
P/E | – |
P/S | 80.21x |
P/B | 50.84x |
P/CF | -34.47x |
P/FCF | -37.75x |
P/OCF | -34.47x |
PEG | -0.36x |
EV multiple | -41.65x |
About
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Similar securities
Based on sector and market capitalization
Report issue